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Abstract. 
Background: Hepatocellular carcinoma (HCC) is a leading cause of liver-related 
mortality in people living with HIV, where co-infection with hepatotropic viruses 
accelerates the course of chronic liver disease.  
Aims: In this study, we hypothesized whether the albumin-bilirubin (ALBI) grade, a more 
accurate marker of liver dysfunction in HCC, might identify patients with progressive 
liver dysfunction in the context of HIV/hepatitis co-infection.  
Methods: Using uni- and multivariable analyses, we studied the ALBI grade as a 
predictor of overall survival (OS) in a large, multi-center cohort of patients with HIV-
associated HCC recruited from 44 centres in 9 countries within the Liver Cancer in HIV 
study group. Patients who underwent liver transplantation were excluded. 
Results: A total of 387 patients, predominantly HCV co-infected (78%) with balanced 
representation of all Barcelona Clinic Liver Cancer (BCLC) stages (A=33%, B=18%, 
C=37%, D=12%) were recruited. At HCC diagnosis, 84% had been on anti-retrovirals for 
a median duration of 8.8 years. The ALBI grade identified significant differences in 
median survival of 97 months for grade 1 (95%CI 13-180 months), 17 months for grade 
2 (95% CI 11-22 months) and 6 months for grade 3 (95%CI 4-9 months, p<0.001). A 
more advanced ALBI grade correlated with lower CD4 counts (464/373/288 cells/mm3 
for grades 1/2/3) and higher HIV viraemia (3.337/8.701/61.845 copies/ml for grades 
1/2/3, p<0.001). 
Conclusions: In this large, multi-center retrospective study, the ALBI grade highlights the 
interplay between liver reserve and immune dysfunction as prognostic determinants in 
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HIV-associated HCC. 
Introduction. 
Liver-related morbidity and mortality is rapidly expanding in people living with HIV, as a 
result of shared transmission modalities between HIV and Hepatitis B (HBV) and C virus 
(HCV) as well as alcohol abuse, which is associated with HIV risk behaviors1. Over the 
past few decades, the consolidated use of combined antiretroviral therapy (cART) has 
dramatically changed the pattern of mortality of people living with HIV, where the 
proportion of deaths from opportunistic infections related to uncontrolled HIV replication 
has reduced in favor of chronic pathologies including cancer2.  
Hepatocellular carcinoma (HCC), the third most lethal malignancy, most frequently 
arises in the context of liver cirrhosis, a highly prevalent condition in patients co-infected 
with HIV and hepatitis3. Liver cirrhosis is not merely a predisposing factor but also a key 
prognostic determinant in patients with HCC, where impairment of liver reserve strongly 
influences treatment decisions4. 
The most widely adopted system to estimate hepatic impairment in HCC patients is the 
Child-Turcotte-Pugh classification, which combines objective biosynthetic parameters 
including circulating albumin, bilirubin and coagulation profile with more subjective 
prognostic traits including the presence and severity of ascites and encephalopathy5. 
Whilst originally devised as a prognostic tool to estimate post-surgical mortality in 
cirrhotic patients without HCC6, the Child-Turcotte-Pugh classification has been 
subsequently incorporated as a biomarker of liver functional reserve in the vast majority 
of staging systems for HCC including the Barcelona Clinic Liver Cancer algorithm 
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(BCLC), the Cancer of the Liver Italian prognostic score (CLIP) and many others7. 
Recent evidence has highlighted potential limitations in the prognostic accuracy of the 
Child-Turcotte-Pugh classification as a biomarker of liver function. On one hand, it has 
been argued that the clinical assessment of ascites and encephalopathy might suffer 
from lack of reproducibility between clinicians8. Secondly, the use of pre-determined cut-
off values applied to laboratory variables might artificially reduce the ability to capture 
more subtle changes in liver function that may be of prognostic significance9. 
To overcome these limitations, which can influence optimal treatment allocation in 
patients with HCC, a novel marker of liver functional reserve based exclusively on 
circulating albumin and bilirubin levels, the albumin-bilirubin (ALBI) grade, has been 
proposed as an alternative to the Child-Turcotte-Pugh class10. Originally derived from 
large patients cohorts of HCC patients and cirrhotic controls, the ALBI grade has 
subsequently been validated in patients of diverse geographical origin and aetiology of 
chronic liver disease11-14 and integrated with currently available prognostic algorithms in 
HCC15, 16. 
However, there is no evidence to support the clinical utility of the ALBI grade in patients 
diagnosed with HIV-associated HCC, a patient population where the progression of liver 
fibrosis is characterized by an accelerated course17. 
The aim of this study was therefore to independently validate the prognostic value of the 
ALBI grade in the setting of a large collaborative study including patients with HIV-
associated HCC derived from Liver Cancer in HIV study cohort.  
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Patients and Methods. 
This retrospective study identified all patients diagnosed with HCC on a background of 
HIV infection in 44 referral centres providing specialist multidisciplinary care for HIV and 
HCC across 9 countries including United States, Canada, Brazil, Argentina, Germany, 
Spain, United Kingdom, Italy and Australia (Supplementary Table 1). Consecutive 
referrals in the period between 1992 and 2016 were collected in a joint database as part 
of an international research consortium using electronic case report forms. Methodology 
of data collection and clinical outcomes pertaining to a proportion of the patients was 
published in 200718. All patients had a diagnosis of HCC either on imaging or by 
histologic criteria according to international guidelines19. To avoid incurring in the 
confounding effect stemming from a fully restored liver function in the prognosis of 
transplant recipients, patients who underwent liver transplantation were excluded 
(n=33), leaving a total of 387 patients eligible for analysis. 
Medical records at each participating institution were searched to derive complete 
demographic, staging and treatment data. All the clinical variables were obtained at 
baseline, defined as the time of HCC diagnosis. HCC staging followed computerized 
tomography and/or magnetic resonance imaging criteria as clinically required to derive 
extent of intra and extra-hepatic spread. Computation of the Child-Turcotte-Pugh 
functional class and BCLC stage followed standard pre-published methodology20. The 
ALBI grade was calculated using the following equation: linear predictor = (log10 bilirubin 
× 0.66) + (albumin × -0.085), where bilirubin is in μmol/L and albumin in g/L. The 
continuous linear predictor was further categorised into 3 different grades for prognostic 
stratification purposes: grade 1 (inferior to -2.60), grade 2 (between -2.60 and -1.39) 
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and grade 3 (above -1.39) as previously described10. 
The primary clinical endpoint of the study was overall survival (OS), calculated from the 
date of diagnosis to patients’ death and/or last follow-up.  
Statistical Analysis. 
Continuous variables were presented as median and range, with associations being 
tested using Mann-Whitney, Kruskal Wallis or Student’s t test as appropriate. 
Categorical variables were presented as frequencies and tested for associations using 
Chi-square or Fisher’s exact test as appropriate.  Kaplan-Meier statistics followed by 
stepwise backward Cox regression was used for uni- and multivariable analyses of 
survival21. We utilised Harrel’s concordance index (c-index) method to rank the different 
prognostic traits according to their predictive ability of discriminating patients according 
to outcome, comparing actual survival outcomes of usable pairs of patients with the 
values of their estimated prognostic indices from the corresponding Cox regression 
model. We adjusted for the overoptimism produced by modelling via comparison with 
150 bootstrap samples. For all analyses, the levels of statistical significance accepted 
was p<0.05. Statistical analyses were performed using SPSS package version 20.0 
(IBM Inc., USA), R Statistical Computing Environment (R Foundation, Vienna, Austria) 
and GraphPad PRISM (GraphPad software inc., La Jolla, CA, USA). 
Results. 
Baseline Patient Characteristics. 
Baseline features of the study cohort are presented in Table 1. Median OS was 96 
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months (95%CI 44-150 months) for patients who received potentially curative therapies 
for HCC (surgical resection, radio-frequency ablation or percutaneous ethanol injection; 
n=121, 31%) compared to 15 months (95%CI 11-19 months) of patients who exclusively 
received non-curative treatments (chemo or radioembolisation, systemic therapies; 
n=123, 32%) and 3.2 months (95%CI 2.4-3.9 months) of patients who received best 
supportive care (n=143, 37%). The majority of patients had a performance status (PS) 
of 0 (n=210, 56%) and classified within Child-Turcotte-Pugh class A criteria (n=214, 
56%). The mean and median follow-up period was 20 and 12 months respectively, with 
216 patients (56%) having died at the time of analysis. 
Nearly all patients had virally-induced chronic liver disease (n=377, 97%) with HCV 
being the leading risk factor in 305 patients (78%). HCV genotype was available in 190 
patients (51%), 153 of whom (78%) were of genotype 1. HCV RNA levels at the time of 
HCC diagnosis were available in 238 patients (74%), with 203 (66%) displaying 
evidence of detectable viraemia. In the 83 patients with HBV-associated HCC (21%), 44 
(53%) had evidence of detectable HBV DNA levels at HCC diagnosis.  
The majority of patients were on cART (n=322, 83%) with a median duration of 
treatment of 8.8 years prior to the diagnosis of HCC. Most patients had undetectable 
HIV viral load at the time of HCC diagnosis (n=240, 65%) and CD4 counts >200 
cells/mm3 (n=265, 69%). The most prevalent risk factor for HIV infection was 
intravenous drug use (n=211, 55%). 
The prognostic performance of the ALBI grade in HIV-associated HCC. 
The ability of the ALBI grade to stratify patients according to OS amongst all patients 
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(n=387) is shown in Figure 1. The median OS in patients with ALBI grade 1 (n=64, 
17%) was 97 months (95%CI 13-180 months) compared to 17 months (95% CI 11-22 
months) of ALBI grade 2 (n=182, 48%) and 6 months (95%CI 4-9 months, of ALBI grade 
3 patients (n=141, 35% p<0.001). Hazard ratios for mortality considering ALBI grade 1 
as reference prognostic category was 2.0 (95%CI 1.3-3.3, p=0.002) for ALBI grade 2 
and 4.7 (95%CI 2.3-7.5, p<0.001) for ALBI grade 3 (Figure 1A).  
When stratified according to Child-Turcotte-Pugh class, OS worsened from 27 months 
(95%CI 14-40) in patients within functional class A (n=215, 56%) to 8 months (95%CI 5-
10 months) in B (n=127, 32%) and 2.6 months (95%CI 0.9-4.3 months) in C (n=45, 
12%), with HRs for mortality of 2.4 (95%CI 1.8-3.3 p<0.001) for the comparison 
between class B versus A and 4.3 (95%CI 2.9-6.4, p<0.001) for class C versus A 
(Figure 1B). 
We further characterized the prognostic potential of the ALBI grade in patients fulfilling 
Child-Turcotte-Pugh A criteria (n=215), where median OS ranged from 97 months 
(95%CI 13-180 months) in ALBI 1 patients to 23 months (95%CI 13-32 months) in ALBI 
2 and 8 months in ALBI 3 patients (95%CI 2-14 months, p<0.001, Figure 1C). We 
evaluated the prognostic role of the ALBI grade in relationship to the type of treatment 
received, confirming its ability to predict for OS in patients receiving radical therapies 
(n=121) where median OS was 96 months (95%CI 13-179 months) in ALBI 1, 53 
months in ALBI 2 (95%CI 30-75 months) and 15 months in ALBI 3 (95%CI 1-31 months, 
Log rank p<0.001). The ALBI grade preserved its stratification potential in patients 
receiving palliative treatments for HCC (n=123), where median OS was 10 months 
(95%CI 8-12 months) in ALBI 1, 7.7 months (95%CI 4.9-10.4 months) in ALBI 2 and 4.5 
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months (95%CI 3.1-5.8 months) in ALBI 3 patients (Log rank p<0.001). 
We verified the value of a number of established prognostic factors in our patient 
population. The BCLC stage accurately predicted for patients’ survival with median OS 
of 41 months in stage A (95%CI 25-57), 11 months in stage B (95%CI 8-15), 9 months in 
stage C (95%CI 6-13) and 3 months in stage D (95%CI 0.8-5 months, p<0.001, Figure 
1D). Other prognostic factors included AFP>400 ng/ml (median OS 27 vs. 5 months, HR 
3.2, 95%CI 2.5-4.3, p<0.001), extrahepatic spread (median OS 16 vs. 4 months, HR 
2.6, 95%CI 1.9-3.6, p<0.001), CD4 count <200 cells/mm3 (median OS 5 vs. 17 months, 
HR 2.0, 95%CI 1.5-2.7, p<0.001), detectable HIV RNA (median OS 7 vs. 18 months, HR 
1.8 95%CI 1.4-2.5, p<0.001), detectable HBV DNA (median OS 6 vs. 29 months, HR 
2.0 95%CI 1.1-3.7, p=0.015) and provision of active anticancer treatment (median OS 
33 vs. 3 months, HR 6.3 95%CI 4.7-8.4, p<0.001). 
To establish their independent prognostic value, ALBI grade and Child-Turcotte-Pugh 
class were tested in multivariable Cox regression models adjusted for BCLC stage. This 
confirmed the independent ability of the ALBI in predicting for patients’ OS (Table 2). 
We subsequently investigated the predictive ability of the ALBI grade alone and 
following adjustment for BCLC stage of the disease using Harrel’s c-index. ALBI grade 
and Child-Turcotte-Pugh class achieved similar predictive accuracy with c-index scores 
of 0.65 (95%CI 0.61-0.68) and 0.66 (95%CI 0.62-0.69) respectively, whereas BCLC 
stage achieved higher accuracy in predicting for OS with a c-index value of 0.70 (95%CI 
0.66-0.74). Combination of BCLC stage with the ALBI grade improved the prognostic 
accuracy of the model, with a resulting c-index of 0.73 (95%CI 0.70-0.76). 
The ALBI grade in HIV-associated HCC. 
 10 
 
The relationship between ALBI grade and clinicopathologic features of the disease. 
In light of the established relationship between HIV-related immune dysregulation and 
the progression of chronic liver disease22, we verified the presence of a correlation 
between ALBI grade and HIV viraemia and CD4 counts at HCC diagnosis. In 371 
patients with evaluable ALBI and HIV RNA levels we found a statistically significant 
difference in HIV viral load within each ALBI grade with median HIV RNA values of 3337 
(95%CI 170-6505) in ALBI 1; 8701 (95%CI 2554-14847) in ALBI 2; and 61845 (95%CI 
10723-112968) copies/ml in ALBI 3 patients (Kruskal-Wallis Chi-square 14.2, DF=2, 
p<0.001, Figure 2A). Similarly, we found an inverse correlation between ALBI grade 
and CD4 counts, with worsening median CD4 cells across patients graded as ALBI 1 
(median 464, 95%CI 402-515), ALBI 2 (median 373, 95%CI 339-407) and ALBI 3 
(median 288, 95%CI 250-325, Kruskal-Wallis Chi-square 32.4, DF=2, p<0.001, Figure 
2B). We found no correlation between ALBI grade and HCV RNA levels (p=0.08) or 
HBV DNA levels (p=0.06) at HCC diagnosis. The ALBI grade maintained its ability in 
predicting OS in patients with detectable (n=44, median OS not reached, 5.9 months 
and 2.5 months for ALBI 1, 2 and 3) and undetectable HBV DNA levels (n=39, median 
OS not reached, 27 months and 10 months for ALBI 1, 2 and 3, Log rank p=0.005). 
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Discussion. 
The incidence of HCC is seven times higher in PLHIV compared to the general 
population23. Despite progressive improvements in the multidisciplinary management of 
both HIV infection and liver cancer, the burden of HCC has been steadily increasing, 
having seen a 23-fold prevalence rise in HCV-co-infected patients over the past 20 
years24. This has been unfortunately mirrored by a consensual increase in mortality, 
where HCC now accounts as a leading cause of death in this patient group, being 
responsible for up to 40% of liver-related events25. 
The tumor-promoting properties of HIV exist by virtue of a synergistic oncogenic effect 
with hepatitis mediated by a faster progression of fibrosis in the context of immune-
depression26, which can be further exacerbated by other co-existing noxae including 
alcohol consumption, cART-induced hepatotoxicity and the presence of an underlying 
metabolic syndrome27. All these factors might not just shape the risk of HCC, but also 
have a direct impact on the tumour microenvironment once HCC is diagnosed, imposing 
an additional toll on residual liver function compared to HIV-negative patients. 
Building on our observation in large cohorts of patients with HCC of various aetiology 
and stage28, we designed this large, collaborative, study to verify whether the prognostic 
role of the ALBI grade, a novel biomarker of liver function, might extend to patients with 
concurrent HIV infection, where HCC has been often depicted as carrying a more 
adverse clinical course29.  
In our consecutive, multi-institutional patient cohort with balanced representation of all 
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the BCLC stages of the disease, we found that the ALBI grade could effectively stratify 
patients according to clinically meaningful differences in median OS ranging from 6 to 
97 months. Previous studies have established that the key advantage of the ALBI grade 
stands in an improved prognostic characterization of patients clustering within the better 
end of the liver functional spectrum. Our results are in support of this view by confirming 
the capacity of the ALBI grade to sub-stratify individuals within Child-Turcotte-Pugh 
class A criteria, where an ALBI score of 1 identifies a subset of patients with median 
survival times of 97 months, a figure that is 4-fold greater compared to that of 
unselected patients fulfilling class A criteria whose median OS is 27 months.  
The improved stratification potential we observed for the ALBI grade holds important 
ramifications in the management of HIV-associated HCC, where the preserved 
prognostic ability of the ALBI in patients undergoing curative and palliative therapies 
confirms the wide clinical applicability of this biomarker. The prognostic dissection of 
patients fulfilling Child-Turcotte-Pugh class A criteria has been proposed to further 
optimize management decisions across the various stages of HCC including early stage 
disease, where ALBI more carefully predicts for post-operative complications30, as well 
as in advanced cases, where the ALBI grade correlates with longer survival and 
increase likelihood to access second-line therapy after sorafenib failure31.  
Whilst it is recognized that HIV status adds a further layer of complexity to the clinical 
management of patients with HCC32, previous studies have been inconsistent in 
addressing the sources of clinical heterogeneity that characterize this special patient 
population where cancer is often diagnosed at an earlier age18 due to a shorter interval 
between infection with HIV/hepatitis and advanced fibrosis3. Initial studies comparing 
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survival outcomes in series of HCC patients matched by HIV status had originally 
reported a significantly shorter survival in HIV-infected patients, with higher intra and 
extra-hepatic disease burden and poor liver function emerging as adverse prognostic 
factors33. However, with the diffusion of standardized screening and treatment strategies 
including adoption of the BCLC staging algorithm from the early 2000s20, HIV status 
vanished as an independent prognostic determinant in subsequent studies, where 
optimal control of HIV infection no longer precluded access to active anticancer 
treatment in the cART era34. 
Despite not stemming from a comparative case-control study with HIV-negative patients, 
our results provide an important contribution to the clinico-pathologic characterization of 
patients with HIV-associated HCC, corroborating the finding that liver functional reserve, 
as measured by the ALBI grade, is a key prognostic determinant in this patient 
population. 
To further substantiate the leading role of liver functional reserve in dictating patients’ 
survival we evaluated the relationship between the ALBI grade and common 
quantitative parameters reflecting HIV infection control. Strikingly, we found a highly 
significant correlation between worsening ALBI grade, higher HIV viraemia and lower 
peripheral CD4 counts, a finding that highlights the important connection between the 
progression of HIV infection and that of underlying liver dysfunction in patients with co-
existing hepatitis and HCC35.  
Such relationship is of greater consequence in co-infected patients, in whom the poorer 
survival figures emerged in comparison to HIV-negative controls cannot be solely 
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explained by the underlying neoplastic disease burden at presentation, which in fact 
seems to be consistently lower in HIV-positive cases, possibly as a result of different 
adherence to screening18, 29. In the absence of robust molecular biomarkers to predict 
the prognosis of HCC in the context of HIV infection, our study provides compelling 
evidence that a routinely available, inexpensive and externally validated biomarker may 
help clinicians to optimize the prognostic assessment of patients with HCC based on an 
improved evaluation of liver functional reserve. 
Unfortunately, our study lacks longitudinal evaluation of the ALBI grade, which might 
have been useful to detect prospective treatment-related changes in liver functional 
reserve. Another important limitation of this study is the lack of longitudinal data on HBV 
and HCV viraemia and the absence of information about subsequent treatment for HCV 
in patients who presented with detectable HCV RNA levels. The recent advent of direct-
acting antiviral therapies characterized by HCV eradication rates >90%36 strengthens 
the importance of evaluating the dynamic changes of the ALBI grade in relationship to 
antiviral therapy in this patient group, an aim that should be explored in future studies37.  
It is conceivable that the relatively wide recruitment times that characterize our patient 
cohort might have influenced patients’ survival. However, the median OS reported 
according to BCLC stage and type of treatment reflect survival rates reported in clinical 
guidelines38. Furthermore, in our study, we verified the value of a number of prognostic 
factors indicative of tumor burden, liver function and HIV infection, confirming a close 
similarity to previously published patient cohorts27, to suggest our patient sample to be 
fully representative of the entire population of HIV-associated HCC. The retrospective 
design should also be acknowledged as a limitation to our work.  However, this study is 
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- to our knowledge - the largest to report survival outcomes in HIV-associated HCC, 
where the multi-centre accrual of consecutive, unselected referrals limits the chances of 
systematic bias. 
In conclusion, this study supports the role of the ALBI grade as a prognostic predictor in 
HIV-associated HCC and warrants prospective validation in future studies. Its prognostic 
ability spans across all the BCLC stages of the disease and its discriminative power in 
predicting patients’ mortality is equal to routinely available liver functional staging 
systems such as the Child-Turcotte-Pugh class, with the advantage of relying 
exclusively on two objective biochemical parameters. The ALBI grade suitably integrates 
with the BCLC staging algorithm to improve its prognostic ability and is able to reflect 
hepatocellular damage relating to HIV-related immune dysfunction and active HIV 
replication, establishing an appealing prognostic relationship between the control of HIV 
infection and progressive liver dysfunction in patients with cirrhosis and superimposed 
HCC.  
Due to its robust pathophysiological foundations and optimal stratifying features, the 
ALBI grade deserves verification as a novel prognostic biomarker in prospective clinical 
studies in a view to potentially incorporate it in routine clinical practice. 
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Figure Legends. 
Figure 1. Kaplan Meier curve analysis showing the effect of the albumin-bilirubin (ALBI) 
grade as predictor of overall survival in the entire patient cohort of patients with HIV-
associated HCC (Panel A), in comparison with the Child-Turcotte Pugh (CTP) class 
(Panel B). Panel C shows the difference in survival according to the ALBI grade in a 
subset of patients with Child-Turcotte Pugh class A cirrhosis (n=215). Panel D illustrates 
the prognostic classification of patients according to the Barcelona Clinic Liver Cancer 
(BCLC) staging system.  
Figure 2. The relationship between the albumin-bilirubin (ALBI) grade and HIV RNA 
levels measured at HCC diagnosis (Panel A). Panel B illustrates median CD4 cell count 
at HCC diagnosis categorized according to ALBI grade. An asterisk (*) marks a level of 
p<0.05.  
 
 
Characteristic N=387 (%) 
Age in years, median (range) 54 (28-74) 
Gender 
Male 
Female 
 
355 (92) 
32 (8) 
Geographical Origin 
North and South America 
Europe 
Australia 
 
290 (75) 
96 (24) 
1 (1) 
Viral etiology of liver disease 
Hepatitis B virus infection 
Hepatitis C virus infection 
 
83 (21) 
305 (78) 
Alcohol Excess 
Absent 
Present 
 
289 (75) 
98 (25) 
AFP  
<400 ng/ml 
>400 ng/ml 
 
239 (65) 
141 (34) 
Albumin, g/L 
Median (range) 
35 (3-52) 
Bilirubin, umol/L 
Median (range) 
18 (4-643) 
AST* (IU/L) 
Median (range) 
81 (12-623) 
ALT (IU/L) 
Median (range) 
55 (9-299) 
INR 
Median (range) 
1.1 (0.9-2.4) 
Platelet count,  
Median (range) 
127 (15-635) 
Child-Turcotte Pugh Score 
A 
B 
C 
 
215 (56) 
127 (32) 
45 (12) 
Albumin-bilirubin Grade  
1 
2 
3 
 
64 (17) 
182 (48) 
141 (35) 
Intrahepatic spread 
Unifocal 
Multifocal (< 50% of liver replacement) 
Massive (>50% of liver replacement) 
 
199 (51) 
105 (27) 
83 (21) 
Maximum diameter of largest lesion 
(cm) 
Median (range) 
 
4.0 (1-20) 
Extrahepatic spread 
Absent 
Present 
 
327 (85) 
60 (15) 
Portal Vein Involvement 
Absent 
Present 
 
306 (80) 
81 (20) 
Performance Status ** 
0 
1 
2 
>2 
 
210 (56) 
98 (26) 
43 (11) 
22 (6) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*AST available on 361 patients. 
** PS available on 373 patients. 
BCLC Stage 
A 
B 
C 
D 
 
126 (33) 
68 (18) 
143 (37) 
50 (12) 
CLIP Score 
0-1 
>2 
 
179 (46) 
208 (54) 
Number of treatment lines for HCC 
0 
1 
>2 
 
140 (37) 
187 (48) 
58 (15) 
Type of treatments for HCC 
Surgical resection 
Radiofrequency Ablation 
Percutaneous Ethanol Injection 
Transarterial chemoembolization 
Radioembolization 
Sorafenib 
Other systemic therapies 
 
59 (14) 
58 (14) 
14 (4) 
130 (34) 
9 (2) 
40 (10) 
7 (2) 
Risk factor for HIV 
Intravenous drug use 
MSM contact 
Heterosexual contact 
Blood products 
Unknown 
 
211 (55) 
52 (13) 
48 (13) 
14 (4) 
63 (16) 
On cART at HCC diagnosis 
Yes 
No 
Missing data 
 
322 (84) 
52 (13) 
13 (3) 
Duration of HIV treatment in years, 
median (range) 
 
8.8 (0-27) 
HIV RNA 
Undetectable 
Detectable 
Missing data 
 
240 (62) 
131 (34) 
16 (4) 
CD4 count, cells/mm3 
Median (range) 
 
330 (5-1423) 
A B
C D
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